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Abstract
Background: We determined direct medical costs, overhead costs, societal costs, and personnel
requirements for the provision of antiretroviral therapy (ART) to patients with AIDS in Haiti.
Methods: We examined data from 218 treatment-naïve adults who were consecutively initiated
on ART at the GHESKIO Center in Port-au-Prince, Haiti between December 23, 2003 and May 20,
2004 and calculated costs and personnel requirements for the first year of ART.
Results: The mean total cost of treatment per patient was $US 982 including $US 846 in direct
costs, $US 114 for overhead, and $US 22 for societal costs. The direct cost per patient included
generic ART medications $US 355, lab tests $US 130, nutrition $US 117, hospitalizations $US 62,
pre-ART evaluation $US 58, labor $US 51, non-ART medications $US 39, outside referrals $US
31, and telephone cards for patient retention $US 3. Higher treatment costs were associated with
hospitalization, change in ART regimen, TB treatment, and survival for one year. We estimate that
1.5 doctors and 2.5 nurses are required to treat 1000 patients in the first year after initiating ART.
Conclusion: Initial ART treatment in Haiti costs approximately $US 1,000 per patient per year.
With generic first-line antiretroviral drugs, only 36% of the cost is for medications. Patients who
change regimens are significantly more expensive to treat, highlighting the need for less-expensive
second-line drugs. There may be sufficient health care personnel to treat all HIV-infected patients
in urban areas of Haiti, but not in rural areas. New models of HIV care are needed for rural areas
using assistant medical officers and community health workers.
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Background
Annual expenditures on HIV/AIDS interventions in
resource-poor countries have increased 30-fold over the
last ten years, to an estimated $US 10 billion in the 2007
[1]. As HIV/AIDS services are rapidly scaled up, determin-
ing the cost of specific HIV/AIDS interventions is critical
in order to evaluate their cost-effectiveness, set program
priorities, and budget for further scale-up [2]. Antiretrovi-
ral therapy (ART) is extremely effective in resource-poor
settings, increasing survival for patients with AIDS from
30% to 90% at one-year [3-7]. However, the only studies
reporting data on the costs of providing ART in resource-
poor settings derived from actual patient experience come
from South Africa, Thailand, and Mexico [8-11]. Few stud-
ies have been conducted in the least developed countries
[12-14] and none of these studies collected patient-level
data. Cost data are a necessary prerequisite to evaluating
the cost-effectiveness of HIV treatment in these severely
resource-constrained settings, which account for the great-
est share of the global burden of HIV disease.
In the current study, we determine direct medical costs,
overhead costs, societal costs, and personnel require-
ments for providing ART to patients with AIDS in Haiti.
Haiti is the poorest country in the Western Hemisphere,
on par with the least developed countries in sub-Saharan
Africa, with a per capita income of $US 380/year and per
capita health expenditure of $US 8/year [15]. The preva-
lence of HIV in Haiti is currently estimated at approxi-
mately 3.8% in the adult population, about half that of
sub-Saharan Africa, which has a regional prevalence of
5.9%, ranging from 3.7% in Angola to 33% in Swaziland
[16,17]. In March 2003, the Global Fund to Fight AIDS,
Tuberculosis, and Malaria (GFATM) granted funding to
Haiti to provide comprehensive HIV/AIDS care which
allowed GHESKIO to begin enrolling large numbers of
patients on ART. The United States President's Emergency
Plan for AIDS Relief (PEPFAR) provided additional sup-
port for the project in January 2004. Previous reports from
Haiti have documented that ART is effective [4,6]. This
report details the cost and personnel requirements of pro-
viding ART during the first year of therapy.
Methods
Study setting
The Haitian Study Group for Kaposi's Sarcoma and
Opportunistic Infections (GHESKIO) was formed in 1982
by a group of Haitian health professionals who described
the first cases of AIDS in a developing country [18]. The
mission of GHESKIO is to provide clinical services and
training, and to conduct research on HIV/AIDS. The clinic
is located in downtown Port-au-Prince; the majority of
patients are urban residents who make less than US$ 1 per
day. The clinic at GHESKIO has provided free HIV coun-
seling, testing, care, and prevention services since 1983.
Beginning in March 2003, the clinic began providing ART
free-of-charge to all patients with AIDS.
All patients presenting to GHESKIO receive HIV voluntary
counseling and testing and screening for other sexually
transmitted diseases. All patients with cough undergo
evaluation for tuberculosis (TB). HIV-infected patients
have a history and physical examination by a physician
and a CD4 cell count is measured. Patients with an AIDS-
defining illness or a CD4 cell count < 200 cells/ml are
started on ART. Prior to starting ART, a complete blood
count, renal function tests and liver enzyme tests are per-
formed, and patients meet with a social worker for ART
counseling and education.
In the GHESKIO ART treatment protocol, patients on ART
are to be seen in the clinic weekly for the first two months
of therapy and then monthly thereafter. At each visit,
patients are seen by a clinician (physician or nurse), and
by a pharmacist who dispenses ART and provides adher-
ence counseling. At three-month intervals, the patients are
to be seen by a social worker for additional counseling.
Laboratory monitoring includes CD4 cell counts, liver
function tests, renal and glucose tests, and complete
blood counts every six months. If an opportunistic infec-
tion is suspected, appropriate laboratory testing is per-
formed.
Patients are referred to on-site sexually transmitted infec-
tion (STI) and family planning clinics when clinically
indicated. TB medications are prescribed in the ART clinic
and dispensed by a nurse in the adjoining GHESKIO TB
clinic. Patients requiring inpatient care are referred to one
of several nearby hospitals in Port-au-Prince. When sub-
specialty care is required (ophthalmology, dermatology,
etc), patients are referred to private providers affiliated
with GHESKIO. Patients with wasting or economic need
receive nutritional supplementation free-of-charge on site
once per month. All patients receive pre-paid telephone
cards and transportation subsidies to facilitate retention
in the program. Clinic staff give the patients pre-paid tele-
phone cards to enhance adherence to medications and
clinic visits; with the cards, the patients can call the clinic
staff free-of-charge.
Health services utilization
We determined actual health care services utilization of
consecutively enrolled treatment-naïve adult AIDS
patients who initiated ART at the GHESKIO clinic from
December 23, 2003 to May 20, 2004. We measured serv-
ice utilization and cost from the societal perspective, and
included all costs that were actually incurred in the month
prior to ART initiation, and for 365 days afterwards. We
collected data from electronic medical records and from
patient charts. For each clinic visit, we extracted: weight;Cost Effectiveness and Resource Allocation 2008, 6:3 http://www.resource-allocation.com/content/6/1/3
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symptoms; active medical conditions; laboratory and
radiographic tests conducted; ART medications and
number of pills dispensed; medications for TB, opportun-
istic infections, and other conditions; nutritional support;
type of provider seen; referrals to specialty care; and hos-
pitalization.
Cost estimates were obtained using the micro-costing
approach outlined by Drummond et al. [19] in which
each component of health care that is utilized (such as
medications and laboratory tests) is recorded and a unit
cost is applied to each component. Costs were measured
in 2004 United States dollars. The cost of ART drugs, anti-
biotics, and other medications stocked in the GHESKIO
pharmacy were provided by GHESKIO. For TB and repro-
ductive health medications provided free-of-charge
through the Haitian Ministry of Health, we used the prices
listed by the International Dispensary Association, a non-
profit supplier of generic medications to Haiti. The costs
of medications not available at the GHESKIO clinic were
obtained from a survey of six private pharmacies in Port-
au-Prince. The cost of laboratory tests (including CD4 cell
counts) that were conducted on-site were obtained from
internal GHESKIO accounting. Chest radiographs were
conducted off-site; we used the price that GHESKIO paid
for each X-ray. Nutrition costs were provided by the non-
governmental organization that provides food supple-
ments to the GHESKIO clinic, and pre-paid telephone
card costs were the price paid for them by GHESKIO. For
cost of hospitalizations, a panel of GHESKIO clinicians
(PL, PS, DWF, and JWP) estimated services utilized on a
case-by-case basis; we estimated the amount paid for the
day of admission and for subsequent days in care. To esti-
mate the cost of each laboratory test, medication, and
radiographic study that was conducted in the hospital, we
used the GHESKIO cost to deliver these services. For spe-
cialty care, we surveyed specialty physicians in Port-au-
Prince to determine the amounts paid for services by these
outside providers; we used charges as they were consistent
with the labor and administrative costs of comparable vis-
its to GHESKIO physicians.
To determine medical personnel utilization and direct
labor costs in the ART clinic, we conducted an observa-
tional study of eight physicians and five nurses to estimate
the average amount of time per visit. Seventy-seven physi-
cian visits and 48 nursing visits were observed by a mem-
ber of the study team, who recorded the number of
minutes each patient spent in the room with each pro-
vider. To limit observational bias, measurements were
conducted from the waiting room at unannounced dates
and times. We found that on average physicians spent 15
minutes and nurses spent 18 minutes with each patient.
We interviewed the TB clinic staff to estimate the time
spent by the TB nurse to dispense medications and pro-
vide adherence counseling (10 minutes per patient). To
estimate the indirect labor cost (for patient care activities
such as recording patient data), we added an additional
50% to the time devoted to face-to-face medical care (i.e.
30 seconds indirect time for each minute of face-to-face
time) based on provider estimates. We then used the
GHESKIO average salary by provider type to determine
the cost of labor per patient based on a provider work
schedule of 200 eight-hour days per year.
Overhead costs were allocated to each visit from actual
expenditures based on clinic patient volume (adjusted for
the duration of patient visits) except for electricity and
cleaning supply costs, which were allocated based on
square footage. Capital costs were annualized and dis-
counted at a rate of 5%. These expenditures had been doc-
umented in financial reports to the GFATM. Societal costs
included non-medical costs (transportation and time)
incurred by the patient. The value of patient time was cal-
culated based on the average wage rate per day reported by
GHESKIO patients, and transportation costs were calcu-
lated according to the patient's residence zone using a
weighted average based on the social worker's estimation
of the percentage of patients who used each type of trans-
portation (walking, public transportation or private taxi)
and its cost (in the case of public transportation or taxi)
for patients arriving from each of 16 Port-au-Prince resi-
dence zones.
Analysis
Data were entered into an Access database (Microsoft,
Redmond, WA) and then converted to SAS Version 9.1
(SAS, Carey NC) for analysis. The primary outcome was
cost of treatment. Direct costs were presented as mean and
median costs with interquartile ranges (see Tables 1 and
2). Secondary outcomes included physician time and
nursing time spent caring for patients. For both primary
and secondary outcomes, we conducted univariate and
multivariate analyses using the following variables: CD4
cell count (measured as a continuous variable), number
of symptoms at treatment initiation, clinical CDC stage
(A, B, C), education (measured as none, primary, second-
ary, or university), income (in five pre-defined income
categories), baseline weight (in quartiles), and age greater
than median, baseline hemoglobin <10 mg/dl, mortality,
hospitalization, TB treatment, change in regimen, and
gender (all measured as binary variables). To examine the
impact of early death and loss to follow-up, we repeated
these analyses for only the patients who remained in care
for the entire year. The arithmetic and geometric means of
the total cost and labor (physician time and nurse time)
were not normally distributed. Therefore, we conducted
the analyses with a generalized linear model (GLM) with
a gamma log link [20]. Variables were maintained in the
multivariate GLM models for p < 0.05. GLM results areCost Effectiveness and Resource Allocation 2008, 6:3 http://www.resource-allocation.com/content/6/1/3
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reported as relative differences, representing the ratio of
the cost, physician time, or nurse time in the presence of
each dichotomized variable (e.g. hospitalization) com-
pared to this value in the absence of each of these varia-
bles (e.g. no hospitalization). There were no sets of
variables in the reported model that showed signs of unac-
ceptable collinearity.
Results
Study population
Between December 23, 2003 and May 20, 2004, 220 treat-
ment-naïve adult AIDS patients initiated ART at the GHE-
SKIO clinic. We reviewed the medical records of 218
(99%) of these patients; we were not able to find two
records. The baseline characteristics of the 218 study
patients are provided in Table 3. Of the 218 patients initi-
ated on ART, 169 (78%) remained in care for one year, 35
(16%) died after a mean time in care of 68 days, and 14
(6%) were lost to follow-up after a mean time in care of
98 days. A total of 20 patients (9%) were hospitalized dur-
ing the study period, and 27 (12%) had a change in ART
regimen due to side effects or treatment failure.
Cost of ART treatment
The mean total cost of treatment per patient was $US 982,
including $US 846 in direct costs, $US 114 for overhead,
and $US 22 for societal costs. For patients who remained
in care for one year, the mean total cost of treatment per
patient was $US 1132. Table 1 presents the mean,
median, and interquartile ranges of direct costs for all
patients in the cohort; Table 2 presents these values for
patients who remained in care for one year.
The mean direct cost per patient included: $US 355 for
ART; $US 130 for laboratory testing and radiographs; $US
117 for food supplementation; $US 62 for hospitaliza-
tion; $US 58 for screening evaluation before ART was ini-
tiated; $US 51 for labor; $US 39 for non-ART medications;
$US 31 for referrals to specialty care outside of the GHE-
SKIO clinic; and $US 3 for telephone cards (Table 1). For
patients who remained in care for one year, the mean
direct cost was $US 972 (Table 2).
The mean overhead costs were $US 114 per patient; the
largest components (Table 4) were indirect clinical costs
($US 26), non-direct health care professional labor ($US
24), monitoring and evaluation ($US 19), electricity ($US
15), and maintenance ($US 15). Mean societal costs were
$US 22 per patient. For patients who remained in care for
one year, mean overhead costs were $US 135 and mean
societal costs were $US 27.
Table 1: Direct treatment utilization and costs for the total cohort (n = 218)
Mean utilization per 
patient for the 1st 
year of ART
Median utilization (IQ 
range) per patient for 
the 1st year of ART
Mean cost per 
patient for the 1st 
year of ART ($US)
Median cost (IQ range) 
per patient for the 1st 
year of ART ($US)
Pre-ART work-up (labor and 
laboratory studies)
* * 58 61 (61 to 61)
Labor cost (# of ART visits) 12.6 14 (11 to 16) 51 51 (42 to 61)
CD4 cell counts** (# of tests) 1.1 1 (1 to 1) 32 30 (30 to 30)
ART monitoring labs (# of tests) 9.5 11 (6 to 12) 72 81 (46 to 92)
TB tests (# of tests) 1.7 0 (0 to 3) 8 0 (0 to 14)
Other laboratory tests (# of tests) 2.7 2 (1 to 3) 8 5 (0 to 13)
Chest radiographs (# of x-rays) 0.4 (0 to 1) 10 0 (0 to 24)
Anti-retroviral therapy (# of days 
on ART)
291 362 (241 to 375) 355 282 (225 to 583)
TB medications (# of days on 
therapy)
19 0 (0 to 0) 6 0 (0 to 0)
Other medications*** * * 33 28 (15 to 40)
Outside referrals 0.3 0 (0 to 0) 31 0 (0 to 0)
Hospitalizations 0.1 0 (0 to 0) 62 0 (0 to 0)
Telephone cards 2.4 2.4 (1 to 3) 3 3 (1 to 4)
Nutritional support * * 117 140 (0 to 180)
Total (# of days in care) 299 365 (357 to 365) 846 846 (654 to 1075)
IQ range = interquartile range
* No utilization units defined.
** This does not include the baseline CD4 cell count done before the initiation of ART; also, many patients had a 12-month CD4 cell count that was 
done more than 365 days after ART initiation, and was therefore excluded from the analysis.
*** GHESKIO paid a mean cost of $US 33.69 per patient for other medications (i.e. not including ART or TB drugs). The mean cost per patient for 
medications purchased outside of GHESKIO was $US 4.31 (median cost of $US 1.23).Cost Effectiveness and Resource Allocation 2008, 6:3 http://www.resource-allocation.com/content/6/1/3
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Predictors of cost: Full cohort
In univariate analyses, predictors of higher treatment cost
included hospitalization ($US 1406 vs. $US 939), change
in ART regimen due to side effects or treatment failure
($US 1308 vs. $US 936), fewer than five symptoms at ART
initiation ($US 1044 vs. $US 853), higher body weight at
baseline ($US 1031 vs. $US 825), and survival for one
year (Table 5). Patients with high body weight and few
symptoms at ART initiation were more likely to survive
and remain in care for a full year. Total costs were signifi-
cantly higher for patients who remained in care ($US
1132) compared with those who died ($US 508) or were
lost to follow-up ($US 382), due to additional days of
treatment. Cost per day in care was significantly higher for
patients who died; they had a higher rate of hospitaliza-
tion (29% vs. 6%) and their cost per day in care was
approximately twice as high ($7.47 per day) as those who
remained in care for one year ($3.10 per day) or were lost
to follow-up ($3.90 per day).
In multivariate analyses, hospitalization, a change in ART
regimen, TB treatment, and survival for one year were sig-
nificantly predictive of higher treatment costs (Table 6).
Survival was associated with higher total treatment costs
because these patients remained in care and used services
for an entire year.
Predictors of cost: Patients who remained in care for one 
year
In univariate analyses of patients who remained in care
for one year, higher costs were associated with hospitali-
zation ($US 1955 vs. $US 1092), a change in ART regimen
due to side effects ($US 1469 vs. $US 1085), TB treatment
($US 1336 vs. $US 1105), and CDC Stage C AIDS symp-
toms at ART initiation ($US 1194 vs. $US 1048) (Table 7).
In multivariate analysis, hospitalization, change in ART
regimen, and older age were associated with significantly
higher treatment costs (Table 8).
Medical personnel utilization
The mean total physician labor time per patient was 2.4
hours, and total nurse labor time per patient was 4.0
hours, including the time of the TB clinic nurse. Assuming
1600 hours per year available for patient care by each doc-
tor or nurse, this implies that 1.5 doctors and 2.5 nurses
are required to treat 1000 patients in the first year after ini-
tiating ART.
In univariate analyses of the total cohort, both physicians
and nurses spent more time with patients with TB, and
with those who survived (Table 5). Physicians also
devoted significantly more time to patients with a change
in ART regimen, no income, and female gender. Patients
Table 2: Direct treatment utilization and costs for patients that remained in care for one full year (n = 169)
Mean utilization 
per patient for the 
1st year of ART
Median utilization (IQ 
range) per patient for 
the 1st year of ART
Mean cost per 
patient for the 1st 
year of ART ($US)
Median cost (IQ range) 
per patient for the 1st 
year of ART ($US)
Pre-ART workup (labor and 
laboratory studies)
* * 58 61 (61 to 61)
Labor cost (# of ART visits) 14.9 15 (14 to 16) 59 54 (47 to 63)
CD4 cell counts** (# of tests) 1.3 1 (1 to 2) 39 30 (30 to 60)
ART monitoring labs (# of tests) 11.3 11 (9 to 13) 85 85 (68 to 99)
TB tests (# of tests) 1.8 0 (0 to 3) 8 0 (0 to 14)
Other laboratory tests (# of tests) 3.2 2 (1 to 4) 9 8 (2 to 13)
Chest radiographs (# of x-rays) 0.4 0 (0 to 1) 10 0 (0 to 24)
Anti-retroviral therapy (# of days on 
ART)
357 367 (355 to 379) 439 413 (273 to 601)
TB medications (# of days on therapy) 21 0 (0 to 0) 6 0 (0 to 0)
Other medications*** * * 37 31 (21 to 42)
Outside referrals 0.4 0 (0 to 0) 39 0 (0 to 19)
Hospitalizations 0.05 0 (0 to 0) 35 0 (0 to 0)
Telephone cards 2.4 3.2 (2 to 3) 3 4 (3 to 4)
Nutritional support * * 145 160 (100 to 200)
Total (# of days in care) 364 365 (365 to 365) 972 923 (770 to 1098)
IQ range = interquartile range
* No utilization units defined.
** This does not include the baseline CD4 cell count done before the initiation of ART; also, many patients had a 12-month CD4 cell count that was 
done more than 365 days after ART initiation, and was therefore excluded from the analysis.
*** GHESKIO paid a mean cost of US$33.69 per patient for other medications (i.e. not including ART or TB drugs). The mean cost per patient for 
medications purchased outside of GHESKIO was $US 4.31 (median cost of $US 1.23).Cost Effectiveness and Resource Allocation 2008, 6:3 http://www.resource-allocation.com/content/6/1/3
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who died consumed more physician time per day in care
(1.2 minutes per day in care) than those who were lost to
follow up (0.8 minutes per day in care) or those who
remained in treatment for the first year (0.5 minutes per
day in care). For nurses, there was little difference in time
per day in care among these patient groups. Nurses spent
1.4 minutes per day in care for patients who died, 1.2
minutes for those who were lost to follow-up, and 1.3
minutes for those who remained in care for the year.
In the multivariate analysis of the total cohort, survival
and TB treatment were associated with greater physician
and nursing time, and a change in ART regimen, hospital-
ization, and female gender were associated with more
physician time (Table 6). In the multivariate analysis of
those who remained in care for the whole year, TB treat-
ment was associated with increased physician and nursing
time, and patients who changed ART regimen and those
who were anemic required more physician time (Table 8).
Discussion
We determined health care utilization, cost, and human
resource requirements for the first year of ART in a cohort
of adult AIDS patients consecutively enrolled in an urban
clinic in Port-au-Prince, Haiti. HIV/AIDS can be effectively
treated in Haiti for approximately US$1000 per patient
per year.
The cost of ART medications comprised only 36% of the
total expenditures and is not the only driver of cost. In
Haiti, patients received generic medications at an average
cost of $US 1.22 per day for a three-drug antiretroviral reg-
imen. This is similar to a recent study from South Africa,
which reported ART costs of $US 1.25 per day, with ART
consuming 23% of the budget [10]. These findings are in
stark contrast to published figures from countries where
generic antiretroviral medications are not routinely used
[21]. In a study conducted in the United States, ART med-
ications accounted for 73% of lifetime medical costs [22].
In a study conducted in Mexico, ART brand named drugs
comprised 85% of the total treatment cost for the first year
on therapy [9].
A change in ART regimen due to side effects or treatment
failure was associated with significantly higher treatment
costs due to the high cost of providing a second-line regi-
men. Many second-line drugs are not available in generic
formulations. For example, the second-line ART drugs
lopinavir/ritonavir and abacavir cost $US 2 and $US 3 per
day each. Furthermore, medication changes required
additional physician time. This highlights the need for
less-toxic first-line regimens and less-expensive generic
second-line drugs for resource-poor settings.
Laboratory tests for the early detection of drug toxicities
and for monitoring response to therapy consumed
approximately 15% of the total cost; however, the utility
of these lab tests is not certain. A recent study conducted
in Thailand investigated the necessity for laboratory toxic-
ity monitoring of ART and concluded that just two lab
tests, an ALT and hemoglobin, could prevent most serious
short-term toxicity [23]. If this study is confirmed, then
Table 3: Baseline characteristics of patients receiving ART (n = 
218)
Female sex – no. (%) 122 (56)
Age – no. (%)
1. <20 yr 2 (2)
2. 20 – 29 yr 25 (12)
3. 30 – 39 yr 83 (38)
4. 40 – 49 yr 74 (34)
5. >49 yr 31 (14)
Resident of Port-au-Prince – no. (%) 191 (88)
Income < $US 1/day – no. (%) 148 (68)
Education – no. (%)
1. None 49 (22)
2. Primary school 67 (31)
3. Secondary school 94 (43)
4. College 8 (4)
Marital status – (%)
1. Common-law marriage 65 (30)
2. Married 37 (17)
3. Separated 54 (25)
4. Single 31 (17)
5. Widowed 26 (12)
AIDS-defining illness (CDC Stage C) – no. (%) 141 (65)
Body weight – kg
1. Men
a) Median 55.5
b) Interquartile range 49.1 to 61.4
2. Women
a) Median 48.4
b) Interquartile range 42.7 to 55.5
CD4 cell count/mm3
1. Median 108
2. Interquartile range 40 to 180
CD4 cell count <50/mm3 – no. (%) 61 (30)
Initial antiretroviral-therapy regimen – no. (%)
1. Nevirapine, zidovudine, lamivudine 111 (51)
2. Other nevirapine-based regimen 5 (2)
3. Efavirenz, zidovudine, lamivudine 92 (42)
4. Other efavirenz-based regimen 10 (5)Cost Effectiveness and Resource Allocation 2008, 6:3 http://www.resource-allocation.com/content/6/1/3
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laboratory monitoring of toxicities could be simplified
and resources saved. Monitoring for treatment failure is
necessary to prevent individual patient morbidity and
mortality, and to prevent emergence of drug-resistant
virus strains. However, a study conducted in Canada sug-
gests that CD4 cell criteria are neither sensitive nor specific
in predicting which patients have failed to achieve viro-
logic suppression [24]. In contrast, a study conducted in
Africa suggests that inexpensive ELISA based p-24 antigen
assays may be very predictive of virologic failure [25].
Table 4: Indirect ART clinic costs, overhead, and societal costs ($US)
Mean cost per patient for total cohort for 
1st year ART ($US)
Mean cost per patient in care for one 
year ($US)
Indirect ART clinic-related costs
Transportation and storage of medications, 
equipment, and supplies
89
ART clinic computers and furniture 18 21
Overhead costs
Monitoring and evaluation 19 22
Non-direct patient care time for health care 
professionals
24 28
Labor for administrative staff 3 4
Electricity 15 18
Maintenance 15 18
Phone and communication 3 4
Office supplies 5 6
Cleaning supplies 3 4
Security 1 1
Total indirect and overhead costs 114 135
Societal costs
Transportation to and from GHESKIO* 16 19
Patient Time at GHESKIO 5 6
Societal costs for outside referrals 
(transportation and patient waiting time)
0.5 1
Societal costs for hospitalization 
(transportation and waiting time for patients 
and family members, and cost of death in the 
hospital)
0.5 1
Total societal costs 22 27
*GHESKIO subsidized transportation fees for all patients ($US 0.60 per ART visit; mean subsidy per patient $US 7.56 per year).
Table 5: Univariate models of cost and medical personnel utilization per patient in the total cohort (n = 218)
Treatment cost Relative difference 95% CI p-value
Survived during observation period (n = 183) 2.11 (1.71, 2.61) <0.0001
Hospitalized during ART (n = 20) 1.50 (1.13, 2.01) 0.0052
ART changed due to side effects (n = 27) 1.40 (1.09, 1.79) 0.0083
Weight above lowest quartile at baseline (n = 155) 1.25 (1.03, 1.52) 0.0244
Fewer than 5 symptoms at ART initiation (n = 147) 1.22 (1.03, 1.46) 0.0238
Physician time Relative difference 95% CI p-value
ART changed due to side effects or failure (n = 27) 1.62 (1.34, 1.97) <0.0001
Survived during observation period (n = 183) 1.59 (2.18, 3.78) <0.0001
Treated for TB (n = 33) 1.58 (1.32, 1.88) <0.0001
Female gender (n = 122) 1.22 (1.07, 1.39) 0.0040
No Income (n = 125) 1.20 (1.05, 1.37) 0.0089
Nurse time Relative difference 95% CI p-value
Treated for TB (n = 33) 1.56 (1.27, 1.90) <0.0001
Survived during observation period (n = 183) 2.13 (1.68, 2.70) <0.0001Cost Effectiveness and Resource Allocation 2008, 6:3 http://www.resource-allocation.com/content/6/1/3
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Using such a simple and inexpensive test to detect viro-
logic failure could improve the quality of HIV care and
reduce cost compared with current recommendations to
monitor CD4 cell counts every six months, if these find-
ings are confirmed [26].
Nutritional support accounted for approximately 10% of
the total cost. This expenditure is critical because Haiti suf-
fers from one of the highest rates of food insecurity in the
world, with nearly two-thirds of its population under-
nourished [15,27]. Wasting is the most common cause of
death in patients with AIDS in Haiti [6]. Studies suggest
that poor nutrition can accelerate HIV disease progression
and death, and that nutritional support may be an effec-
tive intervention for malnourished HIV-infected patients
[28]. Further, we have found that provision of nutritional
support improves adherence to ART and retention in ART
treatment [4]. Transportation subsidies are also critical.
On average, GHESKIO pays half of the transportation
cost, and subsidizes the full amount for patients who miss
clinic visits for economic reasons.
In Haiti, we found that the cost of care was significantly
higher for patients who survived an entire year ($US
1132) than for patients who died (US$ 508). This was due
to the additional number of days in care, even though
those who died had a higher rate of hospitalization, and
their cost per day in care was over twice as high as those
who remained in care for the full year. Most patients who
died on ART did so soon after ART initiation, and access
to advanced tertiary medical care was unfortunately
extremely limited; the situation is similar in other least
developed countries worldwide. This finding differs from
results from better-resourced settings, where hospitaliza-
Table 6: Multivariate models of cost and medical personnel utilization per patient in the total cohort (n = 218)
Treatment cost Relative difference 95% CI p-value
Survived during observation period (n = 183) 3.37 (2.72, 4.17) <0.0001
Hospitalized during ART (n = 20) 2.49 (1.90, 3.25) <0.0001
Treated for TB (n = 33) 1.26 (1.03, 1.54) 0.0275
ART changed due to side effects (n = 27) 1.25 (1.00, 1.56) 0.0491
Physician time Relative difference 95% CI p-value
Survived during observation period (n = 183) 1.97 (1.33, 2.69) <0.0001
Treated for TB (n = 33) 1.54 (1.32, 1.88) <0.0001
ART changed due to side effects or failure (n = 27) 1.30 (0.68, 1.97) 0.0127
Hospitalized during ART (n = 20) 1.27 (1.01, 1.62) 0.0492
Female Gender (n = 122) 1.21 (1.12, 1.50) 0.0005
Nurse time Relative difference 95% CI p-value
Survived during observation period (n = 183) 2.13 (1.68, 2.70) <0.0001
Treated for TB (n = 33) 1.56 (1.27, 1.90) <0.0001
Table 7: Univariate models of cost and medical personnel utilization per patient that remained in care for one full year (n = 169)
Treatment cost Relative difference 95% CI p-value
Hospitalized during ART (n = 8) 1.79 (1.40, 2.28) <0.0001
ART changed due to side effects (n = 21) 1.35 (1.15, 1.59) 0.0002
Treated for TB (n = 20) 1.2 (1.02, 1.43) 0.0276
CDC Stage C (n = 98) 1.14 (1.02, 1.27) 0.0199
Physician time Relative difference 95% CI p-value
Treated for TB (n = 20) 1.83 (1.52, 2.21) <0.0001
ART changed due to side effects (n = 21) 1.36 (1.01, 1.87) <0.0001
CDC Stage C (n = 98) 1.35 (1.18, 1.54) <0.0001
No income (n = 94) 1.21 (1.06, 1.39) 0.0046
Hemoglobin <10 mg/dl at baseline (n = 44) 1.18 (1.01, 1.38) 0.0321
Body weight in the bottom quartile at baseline (n = 33) 1.19 (1.01, 1.41) 0.0479
Female gender (n = 94) 1.16 (1.01, 1.33) 0.0301
Nurse time Relative difference 95% CI p-value
Treated for TB (n = 20) 2.00 (1.70, 2.33) <0.0001
ART changed due to side effects (n = 21) 1.21 (1.01, 1.46) 0.0437
CDC Stage C (n = 98) 1.18 (1.04, 1.33) 0.0309Cost Effectiveness and Resource Allocation 2008, 6:3 http://www.resource-allocation.com/content/6/1/3
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tion, advanced diagnostic tests, intensive care, and medi-
cations for extremely ill patients result in high costs
during the last months of life [9,10,29,30]. Patients in this
study had relatively advanced HIV/AIDS, with a median
CD4 cell count of 108 at study entry; costs may differ in
other settings where patients initiate care with less
advanced disease [21,29,30].
The model of ART employed at GHESKIO requires 1.5
physicians and 2.5 nurses to care for 1000 patients. Haiti
has approximately 2,000 doctors and most of them are
concentrated in urban areas. Therefore, the GHESKIO
model may be feasible in the capital city of Port-au-Prince
and other urban centers. For example, it is estimated that
there are approximately 60,000 HIV-infected people in
Port-au-Prince. If half of them required ART, then 45 phy-
sicians and 75 nurses would be needed to provide care.
However, in rural areas, where there are far fewer physi-
cians and nurses, the GHESKIO model may not be feasi-
ble. Models of ART using assistant medical officers,
community health care workers, and a limited number of
nurses and physicians are needed.
Integration of HIV and TB treatment programs may be a
way to conserve limited resources and health professional
time. In our cohort, co-treatment of tuberculosis and HIV
required only a small increase in cost and physician time
compared with treating HIV alone. Others have argued
that HIV and TB programs in Africa and other resource-
poor settings have many synergies, and that integration
may make both programs more effective [31,32]. Repro-
ductive health services can also be integrated into the HIV/
AIDS clinic. We found that female gender was associated
with increased physician time because women were more
likely to receive reproductive health services, including
treatment in the adjoining sexually transmitted infections
clinic.
Our study was limited to one clinic in Port-au-Prince.
Treatment costs and human resource demands will likely
vary from clinic to clinic. Therefore, alternative models of
care, especially in rural areas, should be the subjects of
future cost and outcomes studies. The costing methodol-
ogy was limited because we used charges instead of costs
for radiographs and specialty care performed outside of
GHESKIO, clinician estimates of hospital service utiliza-
tion, and clinic costs as a proxy for the cost of ancillary
services provided in the hospital. However, these limita-
tions are unlikely to have significantly biased our esti-
mates because of the small proportion of total costs
represented by hospitalizations and other medical serv-
ices performed outside of the GHESKIO clinic.
In summary, HIV/AIDS can be treated in Haiti in the first
year after initiation of ART for about $US 1000 per
patient. With generic first-line antiretroviral drugs, only
36% of the cost was for medications. Patients who change
regimens are significantly more expensive to treat, high-
lighting the need for less expensive second-line drugs.
This model of ART delivery requires 1.5 physicians and
2.5 nurses to care for 1000 patients. There may be suffi-
cient health care personnel to treat all HIV-infected
patients using this model in urban areas of Haiti, but not
in rural areas. New models of HIV care for rural areas
using assistant medical officers and community health
workers are needed. The implications of these findings go
beyond Haiti, to the other least developed countries
worldwide, where tertiary care is frequently unavailable,
health care personnel are scarce in rural areas, and there is
a high prevalence of TB. The total resources required to
provide care will be considerably higher in high HIV/AIDS
prevalence countries of sub-Saharan Africa than in Haiti,
and the shortage of qualified health care personnel in
these countries will place an even greater burden on the
ability to deliver adequate care.
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